Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06628531 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ALI & Pulmonary HA Deposition After SAH

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 18, 2026 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date: Dec 31, 2025 to Sep 30, 2026
    • Study completion date: Sep 30, 2027 to Sep 30, 2026
    v6
  2. Minor Primary completion date: Sep 30, 2025 to Dec 31, 2025
    • Study title revised
    v5
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v4
  4. Notable Start date: Oct 1, 2024 to Dec 1, 2024
    • Study title revised
    v3
  5. Minor Study title revisedv2
  6. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Acute lung injury is a common complication of subarachnoid hematoma (SAH), and a significant risk factor for death in patients with SAH. Unlike neurogenic pulmonary edema and pneumonia following brain injury, the clinical causes of pulmonary injury after SAH are not intracranial hypertension or pulmonary infection. Its occurrence is influenced by the release of catecholamines, the regulatory function of the hypothalamic-pituitary-adrenal (HPA) axis and systemic inflammatory response, but the specific mechanisms are still unclear. Therefore, delving into the pathological mechanisms of SAH-induced lung injury and developing therapeutic strategies based on the findings is of great importance to improve the prognosis of patients. Abnormal accumulation of hyaluronic acid in the lungs has been reported to be closely related to the pathological progression of various pulmonary injury diseases, such as chest trauma, pulmonary infection and chronic obstructive pulmonary disease. From this, the present research is aimed to explore the levels and dynamic changes of hyaluronic acid in the bronchoalveolar lavage fluid and blood of patients with acute lung injury following SAH, and to analyze its correlation with the prognosis of pulmonary complications, thereby providing assistance for the clinical diagnosis and treatment of SAH.
Trial Details
NCT Number NCT06628531
Lead Sponsor Tianjin Medical University
Conditions
(from sponsor)
Subarachnoid Haemorrhage (SAH)
Related terms Acute Lung Injury, Subarachnoid Hemorrhage
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov